Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Sandbrink

Showing results (31-40 of 34) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 34 results.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 21, 2011
Predictive nature of IgM anti-α-glucose serum biomarker for relapse activity and EDSS progression in CIS patients: a BENEFIT study analysisM S Freedman, C Metzig, L Kappos, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 16, 2011
Can the functional assessment of multiple sclerosis adapt to changing needs? A psychometric validation in patients with clinically isolated syndrome and early relapsing-remitting multiple sclerosisS Acaster, P Swinburn, C Wang, et al.
The Pharmacogenomics Journal|November 20, 2002
Elements of informed consent for pharmacogenetic research; perspective of the pharmacogenetics working groupD C Anderson, B Gomez-Mancilla, B B Spear, et al.
Neurology|April 6, 2011
Interferon β-1b and glatiramer acetate effects on permanent black hole evolutionM Filippi, M A Rocca, F Camesasca, et al.
Pageof 4

Showing results (31-40 of 34) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 34 results.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 21, 2011
Predictive nature of IgM anti-α-glucose serum biomarker for relapse activity and EDSS progression in CIS patients: a BENEFIT study analysisM S Freedman, C Metzig, L Kappos, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 16, 2011
Can the functional assessment of multiple sclerosis adapt to changing needs? A psychometric validation in patients with clinically isolated syndrome and early relapsing-remitting multiple sclerosisS Acaster, P Swinburn, C Wang, et al.
The Pharmacogenomics Journal|November 20, 2002
Elements of informed consent for pharmacogenetic research; perspective of the pharmacogenetics working groupD C Anderson, B Gomez-Mancilla, B B Spear, et al.
Neurology|April 6, 2011
Interferon β-1b and glatiramer acetate effects on permanent black hole evolutionM Filippi, M A Rocca, F Camesasca, et al.
Pageof 4